2181 — Mabpharm Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.88bn
- HK$2.09bn
- CNY258.23m
Annual cashflow statement for Mabpharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -185 | -292 | -211 | -209 | -128 |
| Depreciation | |||||
| Non-Cash Items | 38.8 | 19.4 | 20.4 | 24.3 | 27.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -25.8 | 29 | 82 | 182 | 34.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -147 | -199 | -56.9 | 57.4 | -4.1 |
| Capital Expenditures | -197 | -149 | -125 | -19 | -59.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 353 | -30.8 | 20.2 | 15.5 | -38.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 156 | -179 | -105 | -3.5 | -98.2 |
| Financing Cash Flow Items | -10.6 | -10.9 | -4.9 | -29.4 | -9.78 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -80.5 | -17.8 | 112 | 85.6 | 18.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -104 | -403 | -48 | 140 | -84 |